Randi Hagerman, Endowed Chair in Fragile X Research and medical director of the UC Davis MIND Institute, and Robert Hendren, professor, vice chair and director of child and adolescent psychiatry in the UC San Francisco Department of Psychiatry, are the editors of a new leading-edge book, “Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms,” published by Oxford University Press.
The disorders reviewed in the book include psychiatric disorders such as schizophrenia, depression, autism, and ADHD; single-gene disorders such as tuberous sclerosis; fragile X syndrome and associated disorders; phenylketonuria (PKU) and RASopathies; deletion syndromes such as Angelman syndrome; and muscular dystrophies. The book also reviews other complex genetic disorders, such as Down syndrome.
Hagerman, who also is a distinguished professor of pediatrics, is a leader in the treatment of neurodevelopmental disorders, with expertise in targeted treatments that reverse the neurobiological abnormalities associated with a specific condition and are changing the trajectories of development for many of these children.
Hendren‘ research spans a variety of illnesses, from autism, schizophrenia and bipolar disorder to eating and impulse-control disorders. In 2001 he became director of the MIND Institute, where he developed a strong clinical trials program that tested many new treatments for autism. Since 2009 he has served as director of child and adolescent psychiatry at UC San Francisco, where he has conducted numerous clinical studies.
— Do you know of someone who has won an award or accomplished something noteworthy? Email it to email@example.com or send it to Name Droppers, The Davis Enterprise, P.O. Box 1470, Davis, CA 95617